Page last updated: 2024-10-24

caffeine and Parkinsonian Disorders

caffeine has been researched along with Parkinsonian Disorders in 30 studies

Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.

Research Excerpts

ExcerptRelevanceReference
"The objective of this study was to determine comprehensive metabolic changes of caffeine in the serum of patients with parkinsonian disorders including Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) and to compare this with healthy control serum."7.96Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. ( Daida, K; Fujimaki, M; Funayama, M; Hatano, T; Hattori, N; Imamichi, Y; Ishiguro, Y; Ishikawa, KI; Li, Y; Mori, A; Nanmo, H; Nojiri, S; Oji, Y; Okuzumi, A; Saiki, S; Takeshige-Amano, H; Tsunemi, T; Ueno, SI, 2020)
"Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression."7.72Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003)
"The objective of this study was to determine comprehensive metabolic changes of caffeine in the serum of patients with parkinsonian disorders including Parkinson's disease (PD), progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) and to compare this with healthy control serum."3.96Shared Metabolic Profile of Caffeine in Parkinsonian Disorders. ( Daida, K; Fujimaki, M; Funayama, M; Hatano, T; Hattori, N; Imamichi, Y; Ishiguro, Y; Ishikawa, KI; Li, Y; Mori, A; Nanmo, H; Nojiri, S; Oji, Y; Okuzumi, A; Saiki, S; Takeshige-Amano, H; Tsunemi, T; Ueno, SI, 2020)
"Adenosine and its analogues have been shown to induce "behavioral despair" in animal models believed to be relevant to depression."3.72Adenosine A2A receptors and depression. ( Costentin, J; El Yacoubi, M; Vaugeois, JM, 2003)
"Caffeine is a nonselective adenosine receptor antagonist that blocks 2 major types of adenosine receptors, A1AR and A2AAR, in the brain."2.44Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation. ( Ramkumar, V; Toth, LA; Xie, X, 2007)
"3."2.41The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities. ( Angelucci, ME; Canteras, NS; Da Cunha, C; Takahashi, RN; Wonnacott, S, 2002)
"Caffeine, which is a known neuroprotectant, can potentially act as an adjunct to minimise adverse effects of L-DOPA."1.56Caffeine reduces deficits in mechanosensation and locomotion induced by L-DOPA and protects dopaminergic neurons in a transgenic ( Manalo, RVM; Medina, PMB, 2020)
" Parkinson's model was developed by chronic administration of a pesticide rotenone that inhibits mitochondrial complex I resulting in generation of reactive oxygen species."1.51Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression. ( Bandookwala, M; Khairnar, A; Sahu, AK; Sengupta, P; Sharma, M; Thakkar, D, 2019)
"Epigallocatechin gallate (EGCG) is a major component of tea and its known interactions with caffeine make it worthwhile to further study them by investigating the influence of EGCG on the anticataleptic and locomotor-sensitizing effects of caffeine."1.42Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice. ( Acquas, E; Arote, S; Cotti, E; Gaikar, M; Kasture, SB; Kasture, V; Rosas, M; Salve, B, 2015)
"Caffeine-treated samples showed improved binding to phospholipids, a property likely to be important in cellular functioning of α-synuclein."1.42Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease. ( Kardani, J; Roy, I, 2015)
"In order to assess whether caffeine and theophylline have the same potency and efficacy to reverse the impairment of motor function caused by acute or chronic interruption of striatal dopamine transmission, a comparison of their dose-response relationship was made in the acute model of haloperidol-induced catalepsy, and the chronic model of unilateral lesion of the dopamine nigrostriatal pathway with 6-hydroxydopamine."1.39Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats. ( Acuña-Lizama, MM; Alvarez-Cervera, FJ; Bata-García, JL; Góngora-Alfaro, JL, 2013)
"Haloperidol is a classical antipsychotic drug, which produces extra-pyrimidal Parkinson's symptoms (EPS)."1.35Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease. ( Barodia, SK; Luthra, PM; Raghubir, R, 2009)
"(1) Caffeine treatment produced a dose-dependent attenuation of MPTP-induced striatal dopamine loss in both young and retired breeder (RB) male, but not female, mice."1.33Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. ( Ascherio, A; Brown-Jermyn, D; Chen, JF; Dluzen, DE; Schwarzschild, MA; Xu, K; Xu, Y, 2006)
" Acute and chronic administration of CSC was studied to evaluate the possible reversion or prevention of these levodopa effects."1.31Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats. ( Bonastre, M; Bové, J; Marin, C; Tolosa, E, 2002)
"When caffeine was removed, tolerance to bromocriptine effects was observed for 1 day only, while no tolerance was observed to pergolide."1.31Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats. ( Barbanoj, M; Casas, M; Jané, F; Prat, G; Robledo, P; Rubio, A, 2000)

Research

Studies (30)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (56.67)29.6817
2010's10 (33.33)24.3611
2020's3 (10.00)2.80

Authors

AuthorsStudies
Reichmann, H1
Csoti, I1
Koschel, J1
Lorenzl, S1
Schrader, C1
Winkler, J1
Wüllner, U1
Bandookwala, M1
Sahu, AK1
Thakkar, D1
Sharma, M1
Khairnar, A1
Sengupta, P1
Takeshige-Amano, H1
Saiki, S1
Fujimaki, M1
Ueno, SI1
Li, Y1
Hatano, T1
Ishikawa, KI1
Oji, Y1
Mori, A1
Okuzumi, A1
Tsunemi, T1
Daida, K1
Ishiguro, Y1
Imamichi, Y1
Nanmo, H1
Nojiri, S1
Funayama, M1
Hattori, N1
Manalo, RVM1
Medina, PMB1
Kasture, SB1
Gaikar, M1
Kasture, V1
Arote, S1
Salve, B1
Rosas, M1
Cotti, E1
Acquas, E1
Fernández-Dueñas, V1
Gómez-Soler, M1
López-Cano, M1
Taura, JJ1
Ledent, C1
Watanabe, M1
Jacobson, KA1
Vilardaga, JP1
Ciruela, F1
Kardani, J1
Roy, I1
Singhal, NK1
Agarwal, S1
Bhatnagar, P1
Tiwari, MN1
Tiwari, SK1
Srivastava, G1
Kumar, P1
Brashket, S1
Patel, DK2
Chaturvedi, RK1
Singh, MP2
Gupta, KC1
Alisky, J1
Luthra, PM1
Barodia, SK1
Raghubir, R1
Singh, S1
Singh, K1
Gupta, SP1
Singh, VK1
Singh, RK1
Trevitt, J1
Kawa, K1
Jalali, A1
Larsen, C1
Nobre, HV1
Cunha, GM1
de Vasconcelos, LM1
Magalhães, HI1
Oliveira Neto, RN1
Maia, FD1
de Moraes, MO1
Leal, LK1
Viana, GS1
Bata-García, JL2
Tun-Cobá, L1
Alvarez-Cervera, FJ2
Villanueva-Toledo, JR1
Heredia-López, FJ1
Góngora-Alfaro, JL2
Huang, YX1
Luo, WF1
Li, D1
Hu, WD1
Liu, CF1
Gołembiowska, K1
Dziubina, A1
Acuña-Lizama, MM1
Bové, J2
Marin, C2
Bonastre, M1
Tolosa, E1
Da Cunha, C2
Angelucci, ME1
Canteras, NS1
Wonnacott, S1
Takahashi, RN2
Schwarzschild, MA4
Xu, K4
Oztas, E1
Petzer, JP2
Castagnoli, K2
Castagnoli, N2
Chen, JF4
El Yacoubi, M1
Costentin, J1
Vaugeois, JM1
Ren, J1
Porter, JE1
Wold, LE1
Aberle, NS1
Muralikrishnan, D1
Haselton, JR1
Ulanowska, K1
Piosik, J1
Gwizdek-Wiśniewska, A1
We Grzyn, G1
Xu, Y1
Brown-Jermyn, D1
Ascherio, A1
Dluzen, DE1
Serrats, J1
Mengod, G1
Cortés, R1
Aguilar, E1
Xie, X1
Ramkumar, V1
Toth, LA1
Prat, G1
Robledo, P1
Rubio, A1
Barbanoj, M1
Jané, F1
Casas, M1
Staal, R1
Xu, YH2
Beilstein, M1
Sonsalla, PK1
Gevaerd, MS1
Silveira, R1

Reviews

4 reviews available for caffeine and Parkinsonian Disorders

ArticleYear
Life style and Parkinson's disease.
    Journal of neural transmission (Vienna, Austria : 1996), 2022, Volume: 129, Issue:9

    Topics: Caffeine; Exercise; Humans; Life Style; Parkinson Disease; Parkinsonian Disorders

2022
The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.
    Cellular and molecular neurobiology, 2002, Volume: 22, Issue:3

    Topics: Animals; Caffeine; Disease Models, Animal; Humans; Levodopa; Memory Disorders; Neurons; Parkinsonian

2002
Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenosine A1 Receptor Antagonists; Adenosine A2 Recept

2003
Adenosine and dopamine receptor interactions in striatum and caffeine-induced behavioral activation.
    Comparative medicine, 2007, Volume: 57, Issue:6

    Topics: Adenosine; Animals; Behavior, Animal; Caffeine; Corpus Striatum; Dopamine; Humans; Locomotion; Model

2007

Other Studies

26 other studies available for caffeine and Parkinsonian Disorders

ArticleYear
Edaravone-caffeine combination for the effective management of rotenone induced Parkinson's disease in rats: An evidence based affirmative from a comparative analysis of behavior and biomarker expression.
    Neuroscience letters, 2019, 10-15, Volume: 711

    Topics: Animals; Antioxidants; Behavior, Animal; Biomarkers; Brain; Caffeine; Drug Synergism; Edaravone; Lip

2019
Shared Metabolic Profile of Caffeine in Parkinsonian Disorders.
    Movement disorders : official journal of the Movement Disorder Society, 2020, Volume: 35, Issue:8

    Topics: Caffeine; Humans; Metabolome; Multiple System Atrophy; Parkinsonian Disorders; Supranuclear Palsy, P

2020
Caffeine reduces deficits in mechanosensation and locomotion induced by L-DOPA and protects dopaminergic neurons in a transgenic
    Pharmaceutical biology, 2020, Volume: 58, Issue:1

    Topics: Animals; Animals, Genetically Modified; Antiparkinson Agents; Caenorhabditis elegans; Caffeine; Dopa

2020
Tea component, epigallocatechin gallate, potentiates anticataleptic and locomotor-sensitizing effects of caffeine in mice.
    Behavioural pharmacology, 2015, Volume: 26, Issue:1-2

    Topics: Animals; Antipsychotic Agents; Caffeine; Catalepsy; Catechin; Disease Models, Animal; Dose-Response

2015
Uncovering caffeine's adenosine A2A receptor inverse agonism in experimental parkinsonism.
    ACS chemical biology, 2014, Nov-21, Volume: 9, Issue:11

    Topics: Animals; Caffeine; Fluorescence Resonance Energy Transfer; HEK293 Cells; Humans; Mice; Parkinsonian

2014
Understanding Caffeine's Role in Attenuating the Toxicity of α-Synuclein Aggregates: Implications for Risk of Parkinson's Disease.
    ACS chemical neuroscience, 2015, Sep-16, Volume: 6, Issue:9

    Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Caffeine; Cell Survival; Drug Evaluation, Preclinica

2015
Mechanism of Nanotization-Mediated Improvement in the Efficacy of Caffeine Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinsonism.
    Journal of biomedical nanotechnology, 2015, Volume: 11, Issue:12

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Active Transport, Cell Nucleus; Animals; Biological Tr

2015
Coffee as an anti-parkinsonian agent: a case report.
    Journal of alternative and complementary medicine (New York, N.Y.), 2008, Volume: 14, Issue:8

    Topics: Aged, 80 and over; Antiparkinson Agents; Caffeine; Central Nervous System Stimulants; Coffee; Disord

2008
Antagonism of haloperidol-induced swim impairment in L-dopa and caffeine treated mice: a pre-clinical model to study Parkinson's disease.
    Journal of neuroscience methods, 2009, Apr-15, Volume: 178, Issue:2

    Topics: Analysis of Variance; Animals; Antiparkinson Agents; Caffeine; Catalepsy; Corpus Striatum; Disease M

2009
Effect of caffeine on the expression of cytochrome P450 1A2, adenosine A2A receptor and dopamine transporter in control and 1-methyl 4-phenyl 1, 2, 3, 6-tetrahydropyridine treated mouse striatum.
    Brain research, 2009, Aug-04, Volume: 1283

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caffeine; Corpus Striatum; Cytochrome P-450 C

2009
Differential effects of adenosine antagonists in two models of parkinsonian tremor.
    Pharmacology, biochemistry, and behavior, 2009, Volume: 94, Issue:1

    Topics: Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Animals; Caffeine;

2009
Caffeine and CSC, adenosine A2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells.
    Neurochemistry international, 2010, Volume: 56, Issue:1

    Topics: Adenosine A2 Receptor Agonists; Animals; Apoptosis; Caffeine; Cells, Cultured; Encephalitis; Female;

2010
Improvement of postural adjustment steps in hemiparkinsonian rats chronically treated with caffeine is mediated by concurrent blockade of A1 and A2A adenosine receptors.
    Neuroscience, 2010, Mar-17, Volume: 166, Issue:2

    Topics: Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals;

2010
CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
    Brain research, 2011, Feb-28, Volume: 1376

    Topics: Adenosine A2 Receptor Antagonists; Animals; Blotting, Western; Brain; Caffeine; Drug Therapy, Combin

2011
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
    Neurotoxicity research, 2012, Volume: 21, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; D

2012
Caffeine has greater potency and efficacy than theophylline to reverse the motor impairment caused by chronic but not acute interruption of striatal dopaminergic transmission in rats.
    Neuropharmacology, 2013, Volume: 70

    Topics: Animals; Caffeine; Catalepsy; Corpus Striatum; Dopaminergic Neurons; Dose-Response Relationship, Dru

2013
Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.
    Synapse (New York, N.Y.), 2002, Dec-15, Volume: 46, Issue:4

    Topics: Animals; Caffeine; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Purinergic P1 Receptor An

2002
Adenosine A2A receptors and depression.
    Neurology, 2003, Dec-09, Volume: 61, Issue:11 Suppl 6

    Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Antidepressive Agents; Behavior, Animal; Caff

2003
Depressed contractile function and adrenergic responsiveness of cardiac myocytes in an experimental model of Parkinson disease, the MPTP-treated mouse.
    Neurobiology of aging, 2004, Volume: 25, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Caffeine; Calcium; Cell Size;

2004
Formation of stacking complexes between caffeine (1,2,3-trimethylxanthine) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine may attenuate biological effects of this neurotoxin.
    Bioorganic chemistry, 2005, Volume: 33, Issue:5

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Caffeine; Calorimetry; Humans; Models, Molecu

2005
Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2006, Jan-11, Volume: 26, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Caffeine; Corpus Striatum; Cytochrome P-450 CY

2006
Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
    Synapse (New York, N.Y.), 2006, Jun-01, Volume: 59, Issue:7

    Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adenosine;

2006
Effects of sub-chronic combined treatment with pergolide and caffeine on contralateral rotational behavior in unilateral 6-hydroxydopamine-denervated rats.
    Brain research, 2000, Jun-23, Volume: 868, Issue:2

    Topics: Animals; Bromocriptine; Caffeine; Denervation; Drug Administration Schedule; Drug Combinations; Drug

2000
Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2001, May-15, Volume: 21, Issue:10

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Caffeine; Cat

2001
Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats.
    Brain research bulletin, 2001, May-01, Volume: 55, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Avoidance Learning; Caffeine; Central Nervous

2001
Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice.
    Neuroscience letters, 2002, Mar-29, Volume: 322, Issue:1

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Caffeine; Dopamine; Dopamine A

2002